Details of the Drug
General Information of Drug (ID: DMU9O7K)
Drug Name |
Acenanthrene-9,10-dione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1,2-Aceanthrylenedione; Aceanthrenequinone; 6373-11-1; 1,2-Aceanthrenedione; aceanthrylene-1,2-dione; acenanthrene-9,10-dione; Aceanthrenchinon; NSC245130; AC1L7ULB; Aceanthrenequinone, 96%; ACMC-20ap73; SCHEMBL579274; CHEMBL235503; CTK2F3554; BDBM22859; DTXSID90311753; YAIBDWAANBTYIA-UHFFFAOYSA-N; MolPort-002-800-851; 1,2-Dione-Based Compound, 16; 1,2-dihydroaceanthrylene-1,2-dione; MFCD00035767; AKOS015902885; NSC-245130; MCULE-7113625880; VZ20381; CJ-29850; CC-02809; KB-64253; TC-172326; DB-054531; ST50825822; AE-641/00376058; 373A111
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 232.23 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||